Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Healthcare Tech Outlook
THANK YOU FOR SUBSCRIBING
QCell: Trailblazing Medical Diagnosis through Spectral Vision
Follow QCell on :
Costas Balas, Founder, CEO & CSO, QCell
Cancer sometimes goes undetected for months, reducing the chance of survivability when it is eventually large enough to be discovered. Not only is the thought of a biopsy scary enough to discourage people from getting it done, but it is also an excruciating, expensive, and time-consuming procedure. This does bring the necessity of a simpler albeit more effective method of examination. Although this sounds like a dauntingly impossible task, QCell, a medical imaging company, through their patented spectral Vision platform technology, has made optical biopsy a possibility. A culmination of their mastery in biophotonics and hyperspectral imaging.
Almost all medical scopes in effect today work on the principle of colorimetry, restricting the visibility to the physical correlates of color perception. With only three bands of colors in the visible spectrum, the diagnosis is limited to the restraints of the scope. Spectral Vision technology breaks beyond the barriers of the visible spectrum, enabling multichannel visibility. “We can process the information in several spectral bands, including the invisible portions of the spectrum, giving us plenty of opportunities to probe tissue biochemical and microstructural status, which are not visible or detectable with conventional colorimetric devices,” says prof. Costas Balas, Founder, CEO, and CSO at QCell.
With QCell’s spectral scopes, conventional color video imaging is replaced with multichannel video imaging and live spectral mapping, providing an accelerated and precise diagnosis. Spectral Vision technology can acquire an information-rich dataset that feeds AI-based training platforms, transforming spectral maps to live-displayed pathology maps available in vivo, assisting diagnoses, and guiding biopsy sampling and treatments. “Our Spectral Vision technology has enabled us to develop a pipeline of products that not only see this information in real-time but also classifies the information and generates spectral maps,” explains Balas.
The company recently launched Spectral View, the world's first spectral mapping dermoscope. This revolutionary scope provides advanced diagnostic information for a broad spectrum of skin pathologies. It images the skin layers individually and generates functional and compositional maps in real-time, using diffuse reflectance and fluorescence imaging modes.
Spectral Vision technology provides distinct and well defined information that is invisible under normal circumstances
This assists dermatologists to differentiate between melanoma and non-melanoma skin cancers as well as between benign, dysplastic, and melanoma lesions. With the utilization of this technology, skin pathologies can be detected in the initial stages, and appropriate treatment can be prescribed. “This type of modality gives distinct and well-defined information that is not visible under normal circumstances,” extols Balas.
Another product by QCell that has been turning heads is the SAVE (Spectral Artificial Vision Examination) endoscopy workstation, which is an advanced multimodal, multichannel Digital system. It adapts to all typologies of rigid endoscopy applications and establishes spectral patterns for a wide range of diseases. It offers wide contrast and creates spectral patterns and signatures for a wide variety of tissue lesions, enabling improved diagnosis and minimizing the need for a physical biopsy. It has also aided in mapping the grounds of infertility, guiding the implantation of fertilized eggs at the right moment and tissue area. This has reduced the perils of multiple and ectopic pregnancies. “We will continue adding new endoscopes to our product portfolio,” affirms Balas. QCell has also found success in the field of botany, signing a deal with a Chinese company to distribute a non-invasive diagnostic device for plant pathology based on similar principles to the medical scopes but adapted to the nuances of plant pathology. This has aided many agro-based organizations in bettering their outputs.
QCell’s esteemed clientele consists of highly trained and experienced specialist physicians, and they are ecstatic by the ability to see beyond the visible spectrum. They are now able to combine, in real-time ultra-high-definition, accurate spectral information with advanced algorithms to generate diagnostic features and pathology maps.
Illuminating the future of QCell, Balas aims to expand to central and Western Europe and later the U.S. He aspires to gain FDA approval by 2023 and empower the world with its exemplary technology and solution.
Management Costas Balas, Founder, CEO & CSO , QCell
Description QCell is a medical imaging enterprise that empowers the medical field with its patented Spectral Vision technology, enabling better imaging outputs and diagnosis. Breaking beyond the barriers of the visible spectrum and equipped with multi-channel visibility, making optical biopsy a possibility. The company’s technology can acquire an information-rich dataset that feeds AI-based training platforms, transforming spectral maps to live-displayed pathology maps available in vivo, assisting diagnoses, and guiding biopsy sampling and treatments. The cutting-edge technology has made it easy to diagnose pathologies at the earliest and prescribe accurate counter-measures.
This content is copyright protected
However, if you would like to share the information in this article, you may use the link below: